You are here: Industry Insights > Market News > Chinese mainland reports 25 new imported COVID-19 cases

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Chinese mainland reports 25 new imported COVID-19 cases

NMPAOctober 13, 2021

Tag: COVID-19 , mainland , commission

Favorites

BEIJING -- The Chinese mainland on Sunday reported 25 new confirmed COVID-19 cases, all imported from outside the mainland, the National Health Commission said in its daily report on Oct 11.

Among these cases, 14 were reported in Yunnan, four in Shandong, three in Shanghai, two in Guangdong, and one each in Inner Mongolia and Guangxi, according to the commission.

No new suspected cases or new deaths related to COVID-19 were reported on Sunday, said the commission.

Previous:INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization

Next:Ascletis Announces Results of the Phase IIa trial of ASC22 (Envafolimab) in Patients with Chronic Hepatitis B to be Presented in Oral Parallel Session at The Liver Meeting(R) 2021 by American Associat

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023

Biotech NewswireMay 09, 2024

Chinese mainland reports 25 new imported COVID-19 cases | Pharmasources.com

Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore

ACN NewswireMay 09, 2024

The Company will continue to store cord blood units for these clients until the maturity of their service agreements when their children turn 21, without charge.

Chinese mainland reports 25 new imported COVID-19 cases

Related News

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023

Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore

You may like